SCHEMBL29978673

SCHEMBL29978673

CC(C)(C)OC(=O)NC[C@]1(c2cnccn2)NC(=O)NC1=O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 5/20 0.41
ADAMTS5 Q9UNA0 9/20 0.40
MMP2 P08253 5/20 0.38
MMP14 P50281 3/20 0.38
CYP3A4 P08684 2/20 0.36
ADAMTS7 Q9UKP4 2/20 0.35
NAMPT P43490 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
ADAMTS4 O75173 2/20 0.34
MMP1 P03956 2/20 0.34
MMP3 P08254 2/20 0.34
MMP7 P09237 2/20 0.34
MMP9 P14780 2/20 0.34
MMP13 P45452 2/20 0.34
IDO1 P14902 1/20 0.33
LATS1 O95835 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24927817 1.00 ADAM17 (0.41) ADAM17ADAMTS5MMP2MMP14CYP3A4
SCHEMBL23354123 0.84 ADAMTS5 (0.46) ADAM17ADAMTS5MMP2MMP14ADAMTS7
SCHEMBL29873806 0.84 ADAMTS5 (0.46) ADAM17ADAMTS5MMP2MMP14ADAMTS7
SCHEMBL23354411 0.82 ADAMTS5 (0.42) ADAM17ADAMTS5MMP2MMP14CYP3A4
SCHEMBL24938581 0.81 CYP3A4 (0.52) ADAM17ADAMTS5MMP2CYP3A4NAMPT
SCHEMBL29874400 0.81 CYP3A4 (0.52) ADAM17ADAMTS5MMP2CYP3A4NAMPT
SCHEMBL17884921 0.81 ADAMTS5 (0.49) ADAM17ADAMTS5MMP2MMP14ADAMTS4
SCHEMBL29873860 0.81 MMP13 (0.43) ADAM17ADAMTS5MMP2MMP14CYP3A4
SCHEMBL23367190 0.81 MMP13 (0.43) ADAM17ADAMTS5MMP2MMP14CYP3A4
SCHEMBL23354468 0.80 ADAMTS7 (0.52) ADAM17ADAMTS5MMP2MMP14ADAMTS7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 US disclosed
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058448-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 ADAM17 3/4885ADAMTS5 7/4885MMP2 137/4885
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 ADAM17 3/4885ADAMTS5 7/4885MMP2 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.